JPM CBRN Medical - Rapid Acquisition and Investigation of Drugs for Repurposing (RAIDR) - Repurposing Framework

The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation’s biodefense response capability.


OVERVIEW
The JPM CBRN Medical RAIDR - Repurposing Framework (RF) is a complete process that facilitates the rapid delivery of a medical countermeasure (MCM) to the warfighter, or to the general population, as needed. It includes the Repurposing Scorecard and a Repurposing Report format. Together, these tools are used to identify the likelihood that an MCM will make a successful repurposing candidate, compare one MCM against another, maintain records, and communicate results. They are used to socialize repurposing recommendations, and to keep track of the MCMs and associated literature that supports them.

Conceived through the collaboration of a working group of subject matter experts comprised of regulatory and quality analysts, logisticians, strategists, scientists, and attorneys, the RF is a creative way to assess existing medical technology for added benefit. It can provide key medical interventions during the extended period it may take to get effective and specific vaccines and treatments online, much more quickly (months versus years) than standard development and acquisition, without a loss of safety, efficacy, or quality. The RF is used to quickly document findings and provide recommendations to the DOD and other implementing organizations, based on technical reviews. The cost of repurposing is very low relative to development, while maintaining the same medical benefit. Repurposed drugs are more sustainable as they are already in production, with existing infrastructures and supply chains.

 

  • To date, over 33 compounds have been reviewed, and 11 successful deliveries (defined as product in the hands of the people that need them) have been made, due to the RF process.
  • Through the RF process, 12 compounds have applied for National Stock Numbers (NSN), including Remdesivir, which was repurposed from its initial indication to being the COVID-19 standard of care, in less than five months. Remdesivir is presently one of only two authorized treatments for COVID-19.
  • Leukine® (Sargramostim), another repurposed drug, is on a path to delivery for treatment of COVID-19.
  • Humira® (Adalimumab), a rheumatoid arthritis medicine, is presently under review by the repurposing team as a possible treatment for COVID-19.

Coronavirus



Joint Project Manager CBRN Medical Colonel Ryan Eckmeier



"This effort is just one more way the team, with our partners, is 'moving the ball down the field' in the critical pursuit of delivering capability to the Joint Force."

Colonel Ryan Eckmeier
Joint Project Manager for the Chemical, Biological, Radiological, and Nuclear Medical Joint Project Management Office

 

 

RF Flowchart
RF Report Sample